Variables influencing anti-human immunodeficiency virus type 1 neutralizing human monoclonal antibody (NhMAb) production among infected Thais.
We conducted this study to determine the clinical variables associated with the production of human immunodeficiency virus type 1 (HIV-1) circulating recombinant form (CRF) 01_AE neutralizing human monoclonal antibodies (NhMAbs) using a hybridoma technique. This cross sectional study was performed in 20 asymptomatic HIV-1-infected Thais. Peripheral blood mononuclear cells (PBMCs) were obtained from each study participant and fused with SPYMEG cells. Culture supernatant collected from growing hybridomas was tested for neutralizing activity against HIV-1 CRF01_AE Env-recombinant viruses. Fifty hybridomas expressing anti-HIV-1 NhMAbs with strong neutralizing activity against at least 1 CRF01_AE Env-recombinant virus were found. A positive association between the numbers of hybridomas produced and the CD4 counts of study participants (p = 0.019) was observed. NhMAb-producing hybridomas with strong neutralizing activity were mostly found in participans diagnosed with HIV-1 infection within the previous 1 year. The HIV-1 viral load was not significantly correlated with the numbers of either established hybridomas or clones expressing anti-HIV-1 NhMAbs with strong neutralizing activity. To our knowledge, this is the first study of NhMAb-producing hybridomas obtained from HIV-1 CRF01_AE-infected populations identified by antibody binding to HIV-1 V3 loop peptide enzyme-linked immunosorbent assay (ELISA) or TRUGENE HIV-1 Genotyping Assay (HIV-1 pol sequence). It provides important criterion to slect study participants with high CD4 counts who produce large numbers of hybridoma clones. The results are valuable for further studies related to nurtalizing antibodies production and HIV-1 vaccine development.
Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok.
Siriwat
S
Akapirat
The HIV Netherlands, Australia, Thailand Research Collaboration, The Thai Red Cross AIDS Research Center, Bangkok.
Anchalee
A
Avihingsanon
The HIV Netherlands, Australia, Thailand Research Collaboration, The Thai Red Cross AIDS Research Center, Bangkok.
Jintanat
J
Ananworanich
Department of Retrovirology, Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok.
Alexandra
A
Schuetz
Department of Social and Environmental Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok.
Pongrama
P
Ramasoota
Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok.
Natthanej
N
Luplertlop
Ina Laboratory, Medical and Biological Laboratories Corporation, Ltd, Nagano, Japan.
Ken-Ichiro
K
Ono
Research Institute for Microbial Diseases, Osaka University, Japan.
Kazuyoshi
K
Ikuta
Thailand-Japan Research Collaboration Center on Emerging and Re-emerging Infections, Nonthaburi, Thailand.
Piraporn
P
Utachee
Research Institute for Microbial Diseases, Osaka University, Japan.
Masanori
M
Kameoka
Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok.
Pornsawan
P
Leaungwutiwong
D000328:Adult; D057134:Antibodies, Neutralizing / Q000276:immunology*; D018791:CD4 Lymphocyte Count; D004797:Enzyme-Linked Immunosorbent Assay; D005838:Genotype; D015483:HIV Antibodies / Q000097:blood / Q000235:genetics / Q000276:immunology*; D015658:HIV Infections / Q000235:genetics / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D019562:Viral Load
D057134:Antibodies, Neutralizing; D015483:HIV Antibodies